uveal melanoma
Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600E YM-254890 uveal melanoma no benefit detail...
NRAS Q61K YM-254890 uveal melanoma no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00489944 Phase II Cisplatin + Sunitinib + Tamoxifen Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma Unknown status USA 0
NCT01200238 Phase II Ganetespib STA-9090(Ganetespib) in Metastatic Ocular Melanoma Completed USA 0
NCT01430416 Phase I Sotrastaurin Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients Completed USA | NLD | GBR | FRA 0
NCT01471054 Phase II Dexamethasone intravitreal implant Bevacizumab Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma Terminated USA 0
NCT01585194 Phase II Ipilimumab Nivolumab Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma Completed USA 0
NCT01587352 Phase II Vorinostat Vorinostat in Treating Patients With Metastatic Melanoma of the Eye Active, not recruiting USA 0
NCT01835145 Phase II Dacarbazine Temozolomide Cabozantinib Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye Completed USA | CAN 0
NCT01974752 Phase III Dacarbazine + Selumetinib Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Completed USA | NLD | ISR | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BEL 0
NCT01979523 Phase II Trametinib Trametinib + Uprosertib Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma Active, not recruiting USA | GBR | FRA 0
NCT02068586 Phase II Valproic acid Sunitinib Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma Active, not recruiting USA 0
NCT02223819 Phase II Crizotinib Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy Completed USA 0
NCT02273219 Phase I Alpelisib + Sotrastaurin Trial of AEB071 in Combination With BYL719 in Patients With Melanoma Completed USA 0
NCT02359851 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Advanced Uveal Melanoma Terminated USA 0
NCT02363283 Phase II Glembatumumab vedotin Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma Completed USA 0
NCT02561234 Phase I Pegzilarginase A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors Completed USA 0
NCT02570308 Phase I Tebentafusp A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma Completed USA | GBR | ESP | DEU | CAN 0
NCT02601378 Phase I IDE196 + Siremadlin IDE196 A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. Terminated USA | NOR | NLD | FRA | ESP | AUS 0
NCT02645149 Phase II Trametinib Pazopanib Ceritinib Ribociclib + Trametinib Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel) Active, not recruiting AUS 0
NCT02768766 Phase I Selumetinib Intermittent Selumetinib for Uveal Melanoma Completed USA 0
NCT02913417 Phase Ib/II Ipilimumab + Nivolumab + Yttrium-90 microsphere therapy Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases Unknown status USA 0
NCT03022565 Phase I Vorinostat Vorinostat in Patients With Class 2 High Risk Uveal Melanoma Withdrawn 0
NCT03052127 Phase I AU-011 Phase 1B Study in Subjects With Small to Medium Primary Choroidal Melanoma Completed USA 0
NCT03068624 Phase I Aldesleukin + Cyclophosphamide + Ipilimumab Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Uveal Melanoma Active, not recruiting USA 0
NCT03070392 Phase II Dacarbazine Ipilimumab Pembrolizumab Tebentafusp Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma Active, not recruiting USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUS 2
NCT03207347 Phase II Niraparib A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) Completed USA 0
NCT03408587 Phase I Coxsackievirus A21 + Ipilimumab CAVATAK and Ipilimumab in Uveal Melanoma Metastatic to the LIver (VLA-024 CLEVER) (CLEVER) Completed USA 0
NCT03417739 Phase II Ulixertinib A Phase II Study of BVD-523 in Metastatic Uveal Melanoma Active, not recruiting USA 0
NCT03635632 Phase I C7R-GD2.CAR-T cells Cyclophosphamide + Fludarabine C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Active, not recruiting USA 0
NCT03686124 Phase Ib/II IMA-203 ACTengine IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (ACTengine) Recruiting USA | DEU 0
NCT03712904 Phase II Aflibercept Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma Terminated USA 0
NCT03733990 Phase Ib/II FP-1305 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) Completed USA | NLD | GBR | FRA | FIN | ESP 0
NCT03746431 Phase Ib/II 225Ac-FPI-1434 A Phase 1 Study of [225Ac]-FPI-1434 Injection Active, not recruiting USA | CAN | AUS 0
NCT03922880 Phase I ADI-PEG 20 + Ipilimumab + Nivolumab Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma Completed USA 0
NCT03947385 Phase Ib/II IDE196 Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions Recruiting USA | CAN | AUS 0
NCT04109456 Phase I BI 853520 + Cobimetinib BI 853520 IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma Active, not recruiting USA | AUS 0
NCT04116320 Phase I unspecified PD-1 antibody Imiquimod Imiquimod + unspecified PD-1 antibody Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors (AM-003) Terminated USA 0
NCT04130516 Phase Ib/II LNS8801 LNS8801 + Pembrolizumab Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and with Pembrolizumab Recruiting USA 0
NCT04198766 Phase Ib/II INBRX-106 INBRX-106 + Pembrolizumab Carboplatin + INBRX-106 + Nab-paclitaxel + Pembrolizumab Pembrolizumab Cisplatin + INBRX-106 + Pembrolizumab + Pemetrexed Disodium Carboplatin + INBRX-106 + Pembrolizumab + Pemetrexed Disodium Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Recruiting USA 3
NCT04283890 Phase Ib/II Melphalan Ipilimumab + Melphalan + Nivolumab PHP and Immunotherapy in Metastasized UM Active, not recruiting NLD 0
NCT04328844 Phase I Roginolisib A Study to Assess a PI3Kdelta Inhibitor (IOA-244) in Patients With Metastatic Cancers Active, not recruiting ITA | GBR 0
NCT04336241 Phase I Nivolumab + RP2 RP2 Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors Recruiting GBR | ESP 0
NCT04551352 Phase I RO7293583 + Tocilizumab Obinutuzumab + RO7293583 + Tocilizumab A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Completed USA | ESP | DNK | CAN | BEL | AUS 0
NCT04552223 Phase II Nivolumab + Relatlimab Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma Active, not recruiting USA 0
NCT04589832 Phase Ib/II Entrectinib + PAC-1 Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma Terminated USA 0
NCT04720417 Phase II Defactinib + RO5126766 Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal Melanoma Terminated USA 0
NCT04879017 Phase I FHD-286 FHD-286 in Subjects With Metastatic Uveal Melanoma Terminated USA | NLD | FRA 0
NCT04935229 Phase I Ipilimumab + Nelitolimod + Nivolumab Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma Terminated USA 0
NCT04987996 Phase II Pembrolizumab Belapectin + Pembrolizumab GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients Withdrawn USA 0
NCT04993677 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium + SEA-CD40 Pembrolizumab + SEA-CD40 A Study of SEA-CD40 Given With Other Drugs in Cancers Completed USA | SWE | FRA | ESP | DEU | CAN 0
NCT05004025 Phase I Ipilimumab + Nivolumab Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma Completed USA 0
NCT05047536 Phase I KZR-261 KZR-261 in Subjects With Advanced Solid Malignancies Active, not recruiting USA 0
NCT05077280 Phase II Ipilimumab + Nivolumab A Study of Concurrent Stereotactic Body Radiotherapy With Ipi and Nivo in Metastatic Uveal Melanoma Recruiting USA 0
NCT05170334 Phase II Belinostat + Binimetinib Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma Active, not recruiting USA 0
NCT05187884 Phase II IDE196 Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma (NADOM) Active, not recruiting AUS 0
NCT05282901 Phase II Lenvatinib + Pembrolizumab Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME) (PLUME) Active, not recruiting FRA 0
NCT05308901 Phase II Lenvatinib + Pembrolizumab Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naive Metastatic Uveal Melanoma Active, not recruiting USA 0
NCT05315258 Phase II Tebentafusp Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma (TebeMRD) Active, not recruiting GBR 0
NCT05323045 Phase I BYON3521 A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 Completed NLD | ITA | GBR | BEL 0
NCT05415072 Phase Ib/II DYP688 A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas Active, not recruiting USA | NLD | FRA | ESP | DEU | CHE | AUS 0
NCT05482074 Phase II Olaparib Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 Withdrawn 0
NCT05524935 Phase II Olaparib + Pembrolizumab Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma Recruiting USA 0
NCT05542342 Phase II Sitravatinib + Tislelizumab Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. (SITISVEAL) Completed ESP 0
NCT05576077 Phase I Pembrolizumab + TBio-4101 A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (STARLING) Terminated USA | CAN 0
NCT05607095 Phase I Lifileucel Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma Recruiting USA 0
NCT05785754 Phase I Doxorubicin + Tebentafusp DCSZ11 + Pembrolizumab DCSZ11 DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors Recruiting USA | AUS 2
NCT05907954 Phase II IDE196 (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma Recruiting USA | NLD | ITA | GBR | FRA | DEU | CAN | AUS 0
NCT05987332 Phase II Dacarbazine Pembrolizumab Ipilimumab + Nivolumab Crizotinib + IDE196 IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Recruiting USA | POL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUS 0
NCT06070012 Phase II Tebentafusp Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma Recruiting USA 0
NCT06121180 Phase II Aflibercept + Cemiplimab Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma Recruiting USA 0
NCT06246149 Phase III Tebentafusp Adjuvant Tebentafusp in High Risk Ocular Melanoma (ATOM) Recruiting POL | NLD | GBR | FRA | ESP | DEU | BEL 0
NCT06414590 Phase II Tebentafusp Neoadjuvant Tebentafusp for Uveal Melanoma Recruiting USA 0
NCT06519266 Phase III Ipilimumab + Melphalan + Nivolumab Ipilimumab + Nivolumab PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases (SCANDIUM-III) Recruiting SWE 0
NCT06581406 Phase II Nivolumab + RP2 Ipilimumab + Nivolumab A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma (RP2-202) Recruiting USA 0
NCT06626516 Phase Ib/II Tebentafusp Sargramostim + Tebentafusp Carmustine + Tebentafusp Tebentafusp-tebn With LDT in Metastatic UM Recruiting USA 0
NCT06627244 Phase II Tebentafusp Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma Recruiting USA 0
NCT06660420 Phase I PRAME-TCR-NK cells Cyclophosphamide + Fludarabine Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel) Recruiting USA 0
NCT06717126 Phase II Roginolisib A Randomised Phase II Study of Roginolisib in Patients with Advanced/metastatic Uveal Melanoma (OCULE-01) Recruiting ITA | GBR | ESP 0
NCT06805825 Phase I NN3201 A Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced And/or Metastatic Solid Tumors Known to Express C-Kit Recruiting USA 0
NCT06932757 Phase II Quisinostat Adjuvant Quisinostat in High-Risk Uveal Melanoma Recruiting USA 0
NCT06961357 Phase Ib/II Interleukin-12 CD40L-augmented TILs Cyclophosphamide + Fludarabine Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma Recruiting USA 0
NCT07015190 Phase III IDE196 Neoadjuvant Darovasertib in Primary Uveal Melanoma Recruiting USA | POL | NLD | ITA | ISR | GRC | GBR | FRA | EST | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUT | AUS 0
NCT07057596 Phase II Tebentafusp Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma (NEO-TB) Recruiting ESP | DEU 0
NCT07063875 Phase Ib/II Aldesleukin + Tebentafusp Adding IL-2 to Tebentafusp to Eradicate Cancer Progression (SILVER) Recruiting AUS 0
NCT07070232 Phase Ib/II BNT327 + YL202 YL202 Itraconazole + YL202 A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors Recruiting USA | GBR | AUS 0
NCT07136181 Phase Ib/II NBM-BMX Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma (NBM-BMX-UM) Recruiting USA 0
NCT07203391 Phase I Roginolisib + Tebentafusp Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis (TRIUMPH) Recruiting AUS 0